iTeos Therapeutics launched to develop immunomodulators

New Company to Focus on Developing Novel Immunotherapy Compounds for Cancer Treatment

07-May-2012 - Belgium

The Ludwig Institute for Cancer Research (LICR) announced the launch of a private biotechnology enterprise, iTeos Therapeutics SA, to develop a pre-clinical pipeline of immunomodulators to stimulate the immune system’s ability to attack cancer. Founded by LICR with the de Duve Institute at the Université catholique de Louvain (UCL), iTeos is led by a team experienced in tumor immunology, immunotherapy, drug discovery, business development and entrepreneurship. iTeos is the ninth new company formed based on innovative cancer research discoveries licensed from LICR.

iTeos’ initial goals are to reach a proof of concept in humans by completing a Phase I/IIa study for the first compound program and to submit an Investigational New Drug application for a second candidate in four years.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances